Do Probiotics Help Gastritis? What the Science Says

Probiotics show genuine, measurable benefits for gastritis, but mostly as supporting players rather than standalone treatments. The strongest evidence centers on their role alongside antibiotics used to wipe out Helicobacter pylori, the bacterium behind most chronic gastritis worldwide. Adding probiotics to standard drug regimens has been shown to improve cure rates by roughly 10%, cut side effects like diarrhea and nausea by about half, and in some cases reduce the odds of the infection returning. The picture for other types of gastritis and for probiotics used alone is thinner but still interesting, and the details matter more than the headline.

A Quick Look at What Gastritis Is

Gastritis is inflammation of the stomach lining, and its causes determine how well probiotics can help. The major driver is H. pylori infection, which accounts for the vast majority of chronic gastritis cases globally.¹ The infection can simmer for years, gradually damaging the stomach lining and, in a subset of people, progressing toward more serious changes like atrophy or intestinal metaplasia. Other common causes include long-term use of nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen, autoimmune gastritis where the body attacks its own stomach cells, and chemical irritation from bile reflux or alcohol.

Chronic gastritis is classified into non-atrophic and atrophic forms, with the atrophic type further divided based on whether it stems from autoimmune processes or multifocal damage often linked to H. pylori.² This distinction matters for probiotic research because almost all clinical trials have focused on H. pylori-associated gastritis. If your gastritis has a different cause, the evidence base is much smaller.

What Happens to the Stomach’s Microbial Community in Gastritis

The stomach was long thought to be essentially sterile, but it harbors a diverse community of bacteria. In a healthy stomach, the dominant groups include Firmicutes, Bacteroidetes, and Proteobacteria, with genera like Streptococcus and Prevotella making up the largest share.³ When H. pylori moves in, it reshapes the neighborhood. Studies have found that H. pylori colonization shifts the balance toward Proteobacteria and away from Firmicutes, and the functional profile of the microbial community changes too, with enrichment of metabolic pathways and, worryingly, antibiotic resistance genes.⁴

As gastritis progresses, the disruption deepens. Patients with atrophic gastritis carry a significantly higher bacterial load than those with non-atrophic gastritis, and the community becomes more scattered and less stable.⁵ Microbial diversity, measured by standard ecological indexes, tends to be highest in normal stomachs and lowest in stomachs colonized by H. pylori.³ This microbial disruption is part of the rationale for using probiotics: introducing beneficial bacteria to help restore a healthier community and compete against H. pylori.

Boosting H. pylori Eradication Rates

The area where probiotics have the most solid clinical evidence is as add-ons to the antibiotic regimens used to eradicate H. pylori. Standard treatment typically involves two or three antibiotics combined with an acid-suppressing drug, and cure rates with these regimens have been sliding downward in many parts of the world as antibiotic resistance grows. Adding probiotics appears to meaningfully improve those cure rates.

An umbrella review that pooled findings from multiple systematic reviews and meta-analyses found that probiotic supplementation alongside standard therapy was associated with about a 10% relative improvement in eradication rates compared to standard therapy alone.⁶ In absolute terms, individual trials have shown the difference can be dramatic. One trial found that standard triple therapy alone achieved a 69% eradication rate, but adding the probiotic Bifidobacterium infantis pushed that to 83%. Pre-treating patients with the probiotic for two weeks before starting antibiotics pushed the rate even higher, to about 91%.⁷

The benefit also extends to newer treatment regimens. A trial of 14-day high-dose bismuth-containing quadruple therapy with added probiotics achieved a 96% eradication rate, compared to 68% with a shorter 7-day course.⁸ Across the broader literature, the improvement is consistent enough that many gastroenterologists now consider probiotic supplementation a reasonable addition to eradication regimens, particularly in regions where antibiotic resistance is high.

Reducing Antibiotic Side Effects

Even if the eradication-rate boost were modest, probiotics would still earn their keep for a different reason: they substantially reduce the side effects that make people want to quit their antibiotics early. The standard H. pylori regimens are notoriously unpleasant. Patients commonly report diarrhea, nausea, bloating, metallic taste, and abdominal pain, and these side effects are a major reason people abandon treatment before finishing the course.

A network meta-analysis that included 31 studies reporting side effects found that the overall incidence of side effects dropped from about 39% in control groups to roughly 19% in groups receiving probiotics alongside their antibiotics. Rates of diarrhea, abdominal pain, nausea, taste disturbance, vomiting, and constipation all fell significantly.⁹ The umbrella review found a similarly strong reduction in total side effects, with the probiotic groups roughly halving their risk compared to standard therapy alone.⁶

In one double-blind trial testing probiotics with 14-day quadruple therapy, rates of nausea and vomiting dropped from 26% to 6%, abdominal discomfort from 18% to 4%, and bitter taste from 26% to 4% in the probiotic group.⁸ These aren’t trivial improvements. They translate directly into people’s willingness to finish their treatment, which is the single biggest factor in whether eradication actually works.

Symptom Relief for Gastritis Beyond Eradication

A separate question is whether probiotics help with the day-to-day symptoms of gastritis, like stomach pain, bloating, and nausea, independent of whether they’re being used as part of an antibiotic regimen. The evidence here is smaller but positive. A randomized, double-blind, placebo-controlled trial tracked ten gastrointestinal symptoms during and after standard H. pylori treatment. The probiotic group showed statistically significant superiority over placebo for seven of the ten symptoms monitored.¹⁰

In a different setting, an open-label study of airline pilots with chronic non-atrophic gastritis found that probiotic supplementation with Saccharomyces boulardii and Enterococcus faecium significantly reduced subjective gastric pain and bloating compared to a watchful-waiting control group. The benefit held across two different dosage levels.¹¹ That study was small and not blinded, so it carries less weight, but it hints that probiotics may help manage chronic gastritis symptoms even outside the context of active antibiotic therapy.

How Probiotics Actually Work Against Gastric Inflammation

Probiotics don’t just passively crowd out bad bacteria. They appear to act through several mechanisms that are directly relevant to gastritis. In laboratory studies, specific Lactobacillus strains have been shown to physically block H. pylori from attaching to stomach lining cells. Among seven strains tested, Lactobacillus acidophilus and Lactobacillus bulgaricus were the most effective at inhibiting this attachment.¹²

The anti-inflammatory effects go deeper. Lactobacillus acidophilus has been shown to dampen the inflammatory cascade triggered by H. pylori by blocking a key signaling pathway called NF-κB, which is a master switch for inflammatory gene activation. Pre-treating gastric cells with the probiotic reduced the production of inflammatory signals like IL-8 that H. pylori normally provokes.¹³ A 2025 study confirmed and extended these findings, showing that Lactobacillus plantarum ZJ316 reduced multiple inflammatory markers in both cell cultures and in mice with H. pylori infection. Treated mice had less inflammatory cell infiltration in their stomach lining and higher levels of the anti-inflammatory signal IL-10.¹⁴

Which Strains Have the Strongest Evidence

Not all probiotics are interchangeable, and this is one of the most important nuances the research reveals. The strains with the most clinical data for gastritis fall into a few main groups.

Lactobacillus reuteri stands out for having been tested both alone and as an adjunct to standard therapy. Used on its own, L. reuteri has been shown to reduce H. pylori bacterial load and decrease the severity and activity of gastritis in a double-blind placebo-controlled trial, with significant improvement compared to placebo.¹⁵ However, it has not achieved statistical significance in actually curing the infection when used as a single treatment. Its main clinical value as an adjunct is in decreasing gastrointestinal symptoms that cause people to stop therapy early, potentially leading to new antibiotic resistance.¹⁶

Bifidobacterium infantis has shown some of the most impressive eradication-rate improvements in head-to-head trials against standard therapy alone, particularly when given as a pre-treatment before antibiotics begin.⁷ Multi-strain products combining Saccharomyces boulardii with other species have also performed well, especially for bloating and abdominal discomfort. The larger meta-analyses tend to lump all strains together, and the pooled effect is still positive, but the strain-specific differences suggest that the choice of probiotic matters. A generic “probiotic” supplement from the drugstore shelf may or may not contain the strains with the best evidence for gastritis.

Can Probiotics Survive Stomach Acid

A reasonable objection to using probiotics for a stomach condition is that the stomach is designed to kill bacteria. The highly acidic environment (pH 1–3 when fasting) is one of the body’s first lines of defense, and it doesn’t spare probiotic bacteria just because you want them there. Research has confirmed that survival depends heavily on the strain and on what else is in the stomach at the time. Studies on Lactobacillus rhamnosus GG found that the bacteria survived far better in acidic conditions when metabolizable sugars like glucose were present, because the sugar provided fuel for a proton pump that helps the cell expel acid. Without that fuel, survival collapsed dramatically.¹⁷

This has practical implications. Taking probiotics with food, rather than on an empty stomach, likely improves their chances of reaching the stomach lining alive. Many commercial probiotic products use enteric coatings or microencapsulation to protect the bacteria during transit. The fact that clinical trials still show benefits from probiotic supplementation suggests that enough bacteria survive to make a difference, but the delivery format and timing can influence how many get through.

Probiotics and Proton Pump Inhibitors

Proton pump inhibitors (PPIs) like omeprazole are a cornerstone of gastritis treatment, prescribed both to reduce acid and as part of H. pylori eradication regimens. Long-term PPI use, though, carries its own risks: it raises stomach pH dramatically, which can disrupt the normal gut microbial community and increase susceptibility to certain infections. A review of this issue found that probiotic supplementation during PPI therapy may help counteract the resulting dysbiosis. In one study of children receiving PPIs for 12 weeks, intestinal dysbiosis occurred in over half of those not given a probiotic but in only about 6% of those who received Lactobacillus reuteri DSM 17938 alongside their medication.¹⁸

This is an area where the evidence is still developing, but it raises an intriguing possibility: probiotics may be useful not only for treating the infection that caused your gastritis, but also for protecting against the collateral damage from the drugs used to treat it.

NSAID-Induced Gastritis

Gastritis triggered by long-term NSAID use, rather than by H. pylori, is extremely common but far less studied in the context of probiotics. The limited evidence that does exist is mostly preclinical. A 2024 animal study found that probiotic bacteria reduced gastric damage caused by the NSAID indomethacin, lowering markers of oxidative stress and inflammation while boosting antioxidant defenses and inhibiting cell death in the stomach lining.¹⁹ These results are promising in principle but haven’t yet been confirmed in human trials. If you’re dealing with gastritis from regular NSAID use, the current evidence doesn’t support relying on probiotics as a protective strategy, though it does suggest the question is worth pursuing.

Do Probiotics Reduce the Risk of H. pylori Coming Back

Successfully eradicating H. pylori doesn’t guarantee it stays gone. Reinfection or recurrence can happen, particularly in areas where the bacterium is highly prevalent. A 2025 clinical trial specifically designed to address this question found that adding probiotics after standard quadruple therapy cut the recurrence rate roughly in half: about 9% of patients in the probiotic group experienced recurrence, compared to about 19% in the control group. In a statistical model that controlled for other risk factors, probiotic supplementation emerged as an independent protective factor against recurrence.²⁰ Patients in the probiotic group also reported less bloating and antibiotic-associated diarrhea and stuck with their treatment at higher rates.

This is one trial, so the finding needs replication, but it addresses a gap that clinicians have long worried about. If probiotics can reduce recurrence while also making the treatment experience less miserable, the case for routine supplementation during and after eradication therapy gets considerably stronger.

The Compliance Question

You might assume that since probiotics reduce side effects, patients taking them would naturally be more likely to finish their treatment course. The evidence on this is actually mixed. The recurrence trial just mentioned did find higher adherence in the probiotic group (about 92% versus 83%).²⁰ But a systematic review and meta-analysis looking across a broader set of trials found that probiotics plus standard therapy had little or no effect on overall patient compliance.²¹ It’s possible that the side-effect reduction isn’t always large enough to change behavior, or that other factors like pill burden (adding yet another supplement to an already complex regimen) cancel out the comfort gains. Either way, the compliance benefit shouldn’t be taken for granted.

Safety Considerations

For most people, probiotics are well tolerated. The most common side effects are mild gas and bloating, particularly in the first few days. However, theoretical and case-reported risks include systemic infections in severely immunocompromised individuals, excessive immune stimulation in susceptible people, and the possibility of gene transfer between probiotic bacteria and other organisms in the gut.²² If you have a compromised immune system, critical illness, or a central venous catheter, probiotics deserve a conversation with your doctor rather than casual self-prescription. For the general population dealing with gastritis, the safety profile in clinical trials has been consistently reassuring.

Postbiotics and the Next Wave of Research

An emerging area of research sidesteps some of the challenges of live probiotics entirely. Postbiotics are the metabolic byproducts and cell components left behind after probiotic bacteria are killed or broken down. Because they don’t require living organisms, they avoid the survival-in-acid problem and may have a longer shelf life. A 2025 study tested postbiotics derived from Streptococcus thermophilus and Lactobacillus casei, combined with glycyrrhetinic acid (a compound from licorice root), against H. pylori in both cell cultures and a rat gastritis model. The treatment produced substantial reductions in multiple inflammatory markers, including a tenfold decrease in NF-κB expression in some treatment groups and similarly dramatic drops in inflammatory cytokines like TNF-α, IL-1β, and IL-6.²³

These are early-stage findings in cells and animals, not clinical trials in humans. But they suggest that the next generation of gastritis-focused supplements may not need to deliver live bacteria at all. The active ingredients that tamp down inflammation and interfere with H. pylori signaling could eventually be isolated and delivered more reliably. For now, this research is more about where the field is heading than about what you can buy at the pharmacy today.